All News

price%20dollar%20pill.jpg

ACR Applauds Lower Negotiated Prices for Common Arthritis Drugs

d Jack Cush, MD

The American College of Rheumatology praised the recent announcement from the Centers for Medicare & Medicaid Services (CMS) that their initial drug pricing negotiations have reduced costs for select medications, including significantly lower prices for Enbrel and Stelara, which are frequently used to treat rheumatic diseases.

Read Article
RheumNow Podcast square

Higher Cancer Rates (8.16.2024)

d Jack Cush, MD

Dr. Jack Cush reviews the news and journal reports from the past week on RheumNow.com, noting his concerns about diet, cancer, ILD, death and dosing challenges.

Read Article
SI.Sacroiliitis.AS_.jpg

ASLeap: Higher Dose Secukinumab in Ankylosing Spondylitis

d Jack Cush, MD

Ankylosing spondylitis (AS) patients not responding to usual dosing with secukinumab (150 mg) after 16 weeks were dose escalated to secukinumab (SEC) 300 mg, but failed to show improvement by week 52.

Read Article
Gottrons,mechanics

Hispanic Patients With Dermatomyositis

d Jack Cush, MD

JAMA Dermatology has published a review of dermatomyositis (DM), focusing on similar and different manifestations of DM.

DM affects all races, but it has been suggested that racial and ethnic minority patients may have more severe disease and a different autoantibody profile. This analysis characterizes the clinical features and outcomes of DM in Hispanic and non-Hispanic patients.

Read Article
CV,risk,MI,heart,cardiac

Less Mortality with GLP-1 Agonists in Rheumatic Patients

d Jack Cush, MD

A recent article in PLOS ONE has shown that treatment of type 2 diabetes with glucagon-like peptide-1 receptor agonists (GLP-1-RAs) was associated with a significant lowering of risk of all-cause mortality and major adverse cardiovascular events in patients with immune-mediated inflammatory diseases and type 2 diabetes.

Read Article
eyes

Anti-CD40 Therapy in Sjögren's Disease

d Jack Cush, MD

Sjögren's disease is a chronic autoimmune condition without a clear effective therapy - DMARD or biologic. The TWINSS study has demonstrated the safety and efficacy of iscalimab, a monoclonal antibody against CD40, in a phase 2 randomized clinical trial of active Sjögren's disease (SD).

Read Article
Anti-CD40 Therapy in Sjögren's Disease Iscalimab, a CD40 monoclonal antibody, showed + results in treating Sjögren's disease, an autoimmune condition lacking effective therapy. The TWINSS study demonstrated iscalimab's safety/efficacy in a phase 2 trial. https://t.co/aanI9K83XP https://t.co/qJhgHDFCVY

Links:

Dr. John Cush RheumNow ( View Tweet)
Pregnancy, menopause, contraceptives, hormone replacement, aromatase inhibitors may affect lupus outcomes. Review says hormone therapies are contraindicated w/ antiphospholipid syndr, APL Ab positivity, and uncontrolled SLE or flares https://t.co/bZQr8b871n https://t.co/OmXY04GR4p

Links:

Dr. John Cush RheumNow ( View Tweet)
Lung Cancer in Rheumatoid Arthritis and Interstitial Lung Disease A matched cohort study from the Veterans Health Administration shows that RA patients have a >50% increased risk of lung cancer, a 3-fold higher risk of lung cancer in RA-ILD. https://t.co/J9FCdkId8H https://t.co/uJylDP3IIp

Links:

Dr. John Cush RheumNow ( View Tweet)
Romosozumab vs. Teriparatide in Postmenopausal Osteoporosis The effectiveness/safety of ROMO and TPTD were compared in a clinical setting, and ROMO showed greater increases in BMD than TPTD after 12 months of therapy, along with a higher completion rate. https://t.co/iKKLruiiay https://t.co/vPKa8pom7e

Links:

Dr. John Cush RheumNow ( View Tweet)
Anti-Inflammatory Diet yields a lower risk of Dementia. UK Biobank study shows patients w/ type 2 diabetes, heart disease, or stroke who were on an anti-inflammatory diet had a 31% lower risk for dementia vs. a pro-inflammatory diet https://t.co/OjHq3BBOfd https://t.co/tG9vO59IEc

Links:

Dr. John Cush RheumNow ( View Tweet)
Hispanic Patients With Dermatomyositis JAMA Dermatology has published a review of dermatomyositis (DM), focusing on similar and different manifestations of DM. https://t.co/HydzbzTJR4 https://t.co/KJs681ySO7

Links:

Dr. John Cush RheumNow ( View Tweet)
Less Mortality with GLP-1 Agonists in Rheumatic Patients A recent study in PLOS ONE found that treating type 2 diabetes with GLP-1-RAs lowered the risk of mortality and cardiovascular events in patients with IMIDs and type 2 diabetes. https://t.co/MzCG7WvrDS https://t.co/0RPIfOO0s7

Links:

Dr. John Cush RheumNow ( View Tweet)
Rheums! Have a Rheumatology question or case for Jack Cush? Record it here and we'll feature it on an upcoming podcast. Tell us your name and where you practice rheumatology. https://t.co/GV6WjsqZBH https://t.co/9l9qyJpg3I

Links:

Dr. John Cush RheumNow ( View Tweet)
Among the 1st 10 drug prices Negotiated by Medicare - Two are for Rheums: - Etanercept; original price $7,106/Mo], negotiated price $2,355 (67% decr) - Ustekinumab: for original price $13,836/mo, negotiated price $4,695 (66% decr) https://t.co/eexr4Acrbi https://t.co/fE0aoD8vA3

Links:

Dr. John Cush RheumNow ( View Tweet)
More Noninflammatory Pain in Difficult to Treat RA A Canadian cohort of difficult-to-treat rheumatoid arthritis (D2T RA) patients shows significantly more non-inflammatory pain in D2T RA compared to patients responding to b/tsDMARDs. https://t.co/XRH9q0gNyq

Links:

Dr. John Cush RheumNow ( View Tweet)

355 PsA (n=279) & psoriasis (76) pts studied. PsA pts had more comorbidity vs PsO (43% v 26%). >70% low exercise level. Exercise signif improved DAPSA, TJC/SJC, ESR, PASI. Hi Mediterranean diet decr ESR, PASI, but signif only for enthesitis (p 0.015) https://t.co/mdruLj9h5a https://t.co/NOiwXju0wm

Links:

Dr. John Cush RheumNow ( View Tweet)
The Burden of Rheumatoid Arthritis (2018–2020) A recent study that quantified the economic and humanistic burden of RA in the US showed significantly higher health care expenditures, particularly medication costs, and suboptimal quality of life in RA. https://t.co/1v3CDtZC0l https://t.co/WPWuOvpkfa

Links:

Dr. John Cush RheumNow ( View Tweet)
Depends on Where You’re Looking (8.9.2024) https://t.co/GDAN37DJSx https://t.co/jVoumC00r5

Links:

Dr. John Cush RheumNow ( View Tweet)
Mass General Brigham Study 172 RA-ILD pts w/ 6.5 yrs F/U (age 62 yrs): noted (4%) lung transplants & 44 (26%) ILD-related deaths. FVC rapidly declining pts (14%) had aOR 19x lung transplant & aOR 2.8 ILD-related death. Slow decline in 54%, no decline 32% https://t.co/fKDnJIu9a7 https://t.co/ondzN4WZ1F

Links:

Dr. John Cush RheumNow ( View Tweet)

Do you get our email newsletter?

Looking for the latest rheumatology news & trends? Sign up for the RheumNow weekday newsletter:

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Rheumnow.com is a news source dedicated to the field of Rheumatology. It is written by experts in the field, and written for rheumatologists and individuals working in related fields. Rheumnow.com provides daily updates on the site and in your inbox when you are signed up for our newsletter.

Copyright 2024 All Rights Reserved.

×